REVUFORJ (revumenib)
TherapySyndax Pharmaceuticals, Inc.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and REVUFORJ. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where REVUFORJ is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Acute Leukemia Heme · Leukemia | KMT2A
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for REVUFORJ.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering REVUFORJ for eligible patients.
Test
KMT2A Breakapart FISH Probe Kit PDx (CDA-LPH013)
Cytocell Limited (Oxford Gene Technology IP Limited)
Method
FISH
1 approvalView test profile →